Lower drug dose may offer same benefit with fewer side effects for thyroid cancer patients

NCT ID NCT01896479

Ongoing Disease control Sponsor: Exelixis Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a lower dose (60 mg) of the drug cabozantinib works as well as the standard higher dose (140 mg) in people with progressive, metastatic medullary thyroid cancer. The goal is to see if the lower dose can control cancer growth for a similar length of time while causing fewer side effects. About 247 participants took either the lower or higher dose daily, and researchers compared how long their cancer stayed stable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabozantinib (XL184)
What this could lead to: If successful, this could show that a lower dose of cabozantinib works just as well as the higher dose but with fewer side effects, improving quality of life for patients.
What could go wrong: This is a phase 4 study comparing two known doses, so it is not testing a new treatment. The lower dose may prove less effective in controlling cancer progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Carcinoma, Medullary medullary thyroid gland carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MEDULLARY THYROID CANCER

Contacts and locations

Locations

Study site

St Leonards, New South Wales, 2065, Australia
Study site

Herston, Queensland, 4006, Australia
Study site

Kurralta Park, South Australia, 5037, Australia
Study site

Parkville, Victoria, 3050, Australia
Study site

Québec, Quebec, JIH 5N4, Canada
Study site

Toronto, M5G 2M9, Canada
Study site

Osijek, 31000, Croatia
Study site

Zagreb, 10000, Croatia
Study site

Zagreb, 1000, Croatia
Study site

Bordeaux, Gironde, 33076, France
Study site

Angers, Maine-et-Loire, 49933, France
Study site

Lyon, Rhône, 69373, France
Study site

Villejuif, Val-de-Marne, 94805, France
Study site

Dijon, 21079, France
Study site

Paris, 75013, France
Study site

Strasbourg, 67065, France
Study site

Budapest, 1088, Hungary
Study site

Debrecen, 4032, Hungary
Study site

Jerusalem, 91120, Israel
Study site

Petah Tikva, 49100, Israel
Study site

Safed, 13100, Israel
Study site

Catania, CT, 95124, Italy
Study site

Roma, RM, 00161, Italy
Study site

Siena, SI, 53100, Italy
Study site

Pisa, Tuscany, 56124, Italy
Study site

Milan, 20133, Italy
Study site

Padua, 35138, Italy
Study site

Torino, 10153, Italy
Study site

Amsterdam, North Holland, 1066 CX, Netherlands
Study site

Leiden, South Holland, 2333 ZA, Netherlands
Study site

Groningen, 9713 GZ, Netherlands
Study site

Poznan, Greater Poland Voivodeship, 60-355, Poland
Study site

Gliwice, Silesian Voivodeship, 44-100, Poland
Study site

Bucharest, 10825, Romania
Study site

Bucharest, 11863, Romania
Study site

Cluj-Napoca, 400058, Romania
Study site

Timișoara, 300723, Romania
Study site

Novosibirsk, 630068, Russia
Study site

Obninsk, 249036, Russia
Study site

Saint Petersburg, 197089, Russia
Study site

Yaroslavl, 150040, Russia
Study site

Goyang, Gyeonggido, 410769, South Korea
Study site

Seoul, 110744, South Korea
Study site

Seoul, 135-710, South Korea
Study site

Barcelona, 08035, Spain
Study site

Madrid, 28034, Spain
Study site

Madrid, 28046, Spain
Study site

Lund, Skane Ian, SE-22185, Sweden
Study site

Uppsala, Uppsala Ian, 75185, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.